COMPANY RESEARCHModerna is a U.S. biotechnology company developing medicines using messenger RNA technology and related delivery and manufacturing capabilities. Its platform supports the design and production of RNA-based therapeutics and vaccines, with research extending beyond infectious disease into oncology and selected other conditions. Moderna is headquartered in Cambridge, Massachusetts, and its common shares are listed on Nasdaq under MRNA. The company's scientific strategy combines sequence design, drug delivery, clinical development and commercial-scale production.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Moderna is a U.S. biotechnology company developing medicines using messenger RNA technology and related delivery and manufacturing capabilities. Its platform supports the design and production of RNA-based therapeutics and vaccines, with research extending beyond infectious disease into oncology and selected other conditions. Moderna is headquartered in Cambridge, Massachusetts, and its common shares are listed on Nasdaq under MRNA. The company's scientific strategy combines sequence design, drug delivery, clinical development and commercial-scale production.
Nasdaq: MRNA
mRNA therapeutics · lipid nanoparticles
infectious diseases · oncology · rare diseases
Last independently verified:
Disease tags match recorded text mentions and require program-level verification.
A publicly traded mRNA drug company with a disclosed platform spanning mRNA design, LNP delivery, and drug substance and drug product manufacturing.
| Program / service | Target / indication | Representative stage | Evidence & scope |
|---|---|---|---|
| SPIKEVAX / MRESVIA | Project-dependent / not verified · Project-dependent / not verified | Approved (representative vaccine) | Regulatory validation applies to the named vaccine and should not be extended to other programs. |
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Showing 5 / 5 related items
Moderna reported third-quarter 2026 revenue of $1.3 billion, up 29% year over year, and GAAP net income of $162 million, compared with a $200 million loss a year earlier. It raised expected full-year revenue growth to 15%–25% from up to 10%. The company attributed quarterly growth mainly to international COVID vaccine sales supported by government partnerships.
Moderna announced Canadian authorization of mFLUSIVA, its mRNA influenza vaccine, and mCOFLU, its combined influenza and COVID-19 vaccine, for adults 50 and older. The November 5 announcement cites Phase 3 efficacy evidence for mFLUSIVA and immunogenicity comparisons for mCOFLU. The company said it would engage Canadian authorities and immunization partners on future availability.
Moderna reported initial Phase 1/2 MyEngage findings for mRNA-2808, which encodes three T-cell engagers. Four confirmed responses occurred among 11 response-evaluable patients. Twelve patients had received treatment; Grade 3 or higher treatment-related adverse events occurred in 41.7%. These small, uncontrolled findings are preliminary and do not establish comparative benefit.
Moderna reported detailed results from the randomized, double-blind Phase 3 INTerpath-001 trial in completely resected stage IIB–IV melanoma. Adding intismeran autogene to pembrolizumab improved recurrence-free survival in the prespecified intention-to-treat analysis: hazard ratio 0.58 (95% CI 0.45–0.75), with 24.6 months median follow-up. Grade 3–5 treatment-related adverse events occurred in 14.2% versus 13.4%. The treatment remains investigational.
Moderna reported that its Phase 3 safety and efficacy trial of the norovirus vaccine candidate mRNA-1403 did not meet the statistical criteria for early success at an interim analysis. The study remains ongoing and blinded, and the company is preparing to enroll another cohort. The announcement does not establish the final efficacy result or show that the entire trial has failed.
Discussions are for signed-in members. Personal notes remain separate from company research.
Sign in to joinInclusion is not endorsement or partner qualification. Assess company claims, clinical evidence, and project-specific capabilities separately.